Literature DB >> 2068698

Cystic fibrosis. 7. Management of cystic fibrosis in different countries. Cystic fibrosis in Copenhagen.

C Koch1, N Høiby.   

Abstract

Entities:  

Mesh：

Year:  1991        PMID： 2068698      PMCID： PMC1020973          DOI： 10.1136/thx.46.5.385

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  16 in total

Review 1.  Pathogenic mechanisms of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  N Høiby; G Döring; P O Schiøtz
Journal:  Antibiot Chemother (1971)       Date:  1987

2.  Positive expiratory pressure (PEP-mask) physiotherapy improves ventilation and reduces volume of trapped gas in cystic fibrosis.

Authors:  S Groth; G Stafanger; H Dirksen; J B Andersen; M Falk; M Kelstrup
Journal:  Bull Eur Physiopathol Respir       Date:  1985 Jul-Aug

3.  Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.

Authors:  J M Littlewood; M G Miller; A T Ghoneim; C H Ramsden
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

4.  Improving the ketchup bottle method with positive expiratory pressure, PEP, in cystic fibrosis.

Authors:  M Falk; M Kelstrup; J B Andersen; T Kinoshita; P Falk; S Støvring; I Gøthgen
Journal:  Eur J Respir Dis       Date:  1984-08

5.  Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis.

Authors:  S Suter; U B Schaad; P Roux-Lombard; E Girardin; G Grau; J M Dayer
Journal:  Am Rev Respir Dis       Date:  1989-12

6.  Frequency of Aspergillus fumigatus isolates and antibodies to aspergillus antigens in cystic fibrosis.

Authors:  H Schønheyder; T Jensen; N Høiby; P Andersen; C Koch
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1985-04

7.  The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  T Jensen; S S Pedersen; C H Nielsen; N Høiby; C Koch
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

8.  Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.

Authors:  T Jensen; S S Pedersen; S Garne; C Heilmann; N Høiby; C Koch
Journal:  J Antimicrob Chemother       Date:  1987-06       Impact factor: 5.790

9.  Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.

Authors:  S S Pedersen; T Jensen; N Høiby; C Koch; E W Flensborg
Journal:  Acta Paediatr Scand       Date:  1987-11

10.  Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis.

Authors:  M Szaff; N Høiby
Journal:  Acta Paediatr Scand       Date:  1982-09
View more
  3 in total

1.  The cost of care in cystic fibrosis.

Authors:  D J Shale
Journal:  Thorax       Date:  1992-09       Impact factor: 9.139

2.  Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre.

Authors:  M Nir; S Lanng; H K Johansen; C Koch
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

3.  Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis.

Authors:  Tavs Qvist; David Taylor-Robinson; Elisabeth Waldmann; Hanne Vebert Olesen; Christine Rønne Hansen; Inger Hee Mathiesen; Niels Høiby; Terese L Katzenstein; Rosalind L Smyth; Peter J Diggle; Tania Pressler
Journal:  J Cyst Fibros       Date:  2015-10-09       Impact factor: 5.482
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.